Oncotype DX® AR-V7 Nucleus Detect™ - Phil Febbo, MD

(Length of Discussion: 40 sec)

Dr. Phil Febbo, chief medical officer of Genomic Health, discusses a new test to guide treatment in metastatic prostate cancer.

Read More:

Launch of Oncotype DX® AR-V7 Nucleus Detect™ Test Expands Offering to Prostate Cancer Patients - Predicting Treatment Response in Metastatic Disease

Biography: Phil Febbo, M.D. Chief Medical Officer After 20 years as a physician scientist at leading Institutes throughout the country, Phil Febbo, joined Genomic Health as Chief Medical Officer in 2013. Immediately prior to Genomic Health, Phil served as Professor of Medicine and Urology at the University of California, San Francisco where his laboratory focused on using genomics to understand the biology and clinical behavior of prostate cancer, and his clinical practice focused on genitourinary oncology.
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe